HCA Healthcare, Inc. (NYSE: HCA)

$375.00 ▼ -11.87 (-3.07%)

As of Jun 18, 2026 04:00 PM

Sector: Healthcare Industry: Medical Care Facilities CIK: 0000860730

Market Cap 83.85 Bn

P/E 12.74

P/S 1.10

Div. Yield 0.01

ROIC (Qtr) -0.03

Total Debt (Qtr) 48.02 Bn

Revenue Growth (1y) (Qtr) 4.30

Add ratio to table...

About

HCA Healthcare, Inc. is a leading health care services provider in the United States, operating a vast network of hospitals and outpatient facilities. The company delivers a comprehensive range of medical services, including general acute care, behavioral health, and rehabilitation, alongside outpatient services such as ambulatory surgery centers, emergency care, and diagnostic imaging. With 190 hospitals and 152 freestanding outpatient centers across 19 states and England as of December 31, 2025, HCA Healthcare focuses on delivering high-quality,...

HCA Healthcare, Inc. is a leading health care services provider in the United States, operating a vast network of hospitals and outpatient facilities. The company delivers a comprehensive range of medical services, including general acute care, behavioral health, and rehabilitation, alongside outpatient services such as ambulatory surgery centers, emergency care, and diagnostic imaging. With 190 hospitals and 152 freestanding outpatient centers across 19 states and England as of December 31, 2025, HCA Healthcare focuses on delivering high-quality, cost-effective care through a blend of inpatient and outpatient offerings.

HCA Healthcare generates revenue primarily through patient services, reimbursed by government programs, private insurers, and direct payments. In 2025, the company reported $75.6 billion in revenues, with the largest share coming from managed care and other private insurers, accounting for 48.9% of total revenues. Medicare and Medicaid contributed 14.9% and 7.8%, respectively, while managed Medicare and Medicaid programs added 17.8% and 4.9%. The company also serves uninsured patients, who represented 3.2% of revenues, and international patients, contributing 2.5%. Reimbursement rates vary by payer, with government programs typically offering lower rates than private insurers, and the company negotiates contracts with managed care plans to secure favorable terms.

The company operates through distinct service lines that form its core operational segments.

• General Acute Care Hospitals: This segment includes 179 hospitals with 50,436 licensed beds, providing a full spectrum of inpatient and outpatient services. These hospitals offer medical and surgical specialties such as cardiology, oncology, orthopedics, and obstetrics, along with diagnostic, emergency, and ancillary services. They also operate outpatient facilities, including surgery centers, urgent care clinics, and diagnostic centers, to create integrated care networks in local communities.

• Behavioral Hospitals: HCA Healthcare operates seven behavioral hospitals with 714 licensed beds, delivering mental health and substance abuse treatment. Services include inpatient psychiatric care, partial hospitalization, and outpatient programs for children, adolescents, and adults. These facilities address a critical need for specialized mental health services within the broader health care system.

• Rehabilitation Hospitals: The company owns four rehabilitation hospitals, focusing on intensive physical and occupational therapy for patients recovering from strokes, spinal cord injuries, and other debilitating conditions. These facilities provide specialized care to restore functional independence and improve patient outcomes.

• Outpatient Services: This segment encompasses 121 freestanding ambulatory surgery centers and 31 endoscopy centers, offering cost-effective alternatives to hospital-based procedures. These centers perform a wide range of outpatient surgeries and diagnostic services, often in partnership with physicians, and are designed to enhance accessibility and efficiency for patients and providers.

HCA Healthcare holds a dominant position in the U. S. health care industry, ranking as one of the largest hospital operators by revenue and facility count. The company competes with other for-profit hospital chains, such as Tenet Healthcare and Community Health Systems, as well as not-for-profit and government-owned hospitals. Its competitive advantages include a vast network of facilities, economies of scale in purchasing and operations, and a strong focus on clinical quality and patient satisfaction. The company leverages its size to negotiate favorable contracts with suppliers and insurers, while its investment in digital and artificial intelligence capabilities enhances operational efficiency and care coordination. However, HCA Healthcare faces challenges from regulatory pressures, labor shortages, and competition from freestanding specialty providers.

HCA Healthcare serves a diverse customer base, including patients covered by government programs like Medicare and Medicaid, as well as those with private insurance through employers or health exchanges. The company also treats uninsured patients, who often access care through emergency rooms, and international patients seeking specialized medical services. While the filing does not disclose specific customer names, HCA Healthcare’s payer mix reflects broad engagement with managed care organizations, commercial insurers, and government agencies. The company’s facilities are concentrated in high-growth markets, particularly Florida and Texas, where it benefits from strong demand for health care services.

Investment thesis

Bull case

HCA’s 2025 results demonstrate a robust revenue base with a 6.7% year‑over‑year increase, driven by a combination of network expansion and high occupancy rates that consistently hover above 72%. The company’s ability to maintain a 20%+ adjusted EBITDA margin amid rising costs indicates strong pricing power and effective cost management, which is a key lever for sustaining profitability as the healthcare environment evolves. Moreover, the strategic capital allocation plan—highlighted by $5–$5.5 billion in 2026 capital spending—focuses on high‑acuity inpatient facilities and outpatient surgical centers, positioning HCA to capture the anticipated shift toward outpatient care and less invasive procedures, a trend that is expected to outpace inpatient volumes.
The digital transformation agenda, particularly the AI‑driven revenue cycle and capacity‑management initiatives, has already yielded measurable improvements in days in accounts receivable and operational efficiency. By standardizing data across its 190 hospitals and 2,500 ambulatory sites, HCA is creating a scalable platform that can be leveraged for future predictive analytics and clinical decision support, potentially driving higher quality outcomes and lower readmission rates. The company’s recent recognition on Healthgrades’ top hospital lists reinforces its clinical excellence narrative, which can enhance payer negotiations and attract higher‑volume referral traffic, thereby supporting incremental revenue growth.
HCA’s shareholder return policy is aggressive yet disciplined: a $10 billion share‑repurchase program, a quarterly dividend increase from $0.72 to $0.78, and $2.6 billion in repurchases during 2025. This signals management confidence in the company’s cash generation capabilities, with operating cash flow projected at $12–$13 billion in 2026, comfortably covering debt service and supporting future capital deployments. The low debt‑to‑adjusted EBITDA leverage range further underpins the firm’s ability to maintain a healthy balance sheet while investing in growth and returning capital to shareholders.
The resiliency program, quantified at a $400 million EBITDA offset in 2026, addresses the projected $600–$900 million headwind from health insurance exchange reforms and the expiration of enhanced premium tax credits. By combining revenue integrity initiatives, cost efficiencies, and capacity management, the program is positioned to partially neutralize policy‑induced revenue erosion, preserving margin expansion. This proactive stance mitigates one of the most significant regulatory risks facing large health systems and can provide a competitive edge over peers less prepared for the exchange transition.
HCA’s outpatient expansion strategy is particularly compelling; the company added approximately 100 new outpatient facilities in 2025 and continues to pursue acquisitions that complement its geographic footprint. Outpatient surgery volumes, though flat in 2024, are projected to grow as patient preference shifts toward minimally invasive procedures and lower cost settings. With 39.7% of total revenues coming from outpatient sources—a figure already above the industry average—HCA is well positioned to capture the long‑term shift toward ambulatory care, reinforcing its revenue diversification and resilience against inpatient downturns.

HCA’s 2025 results demonstrate a robust revenue base with a 6.7% year‑over‑year increase, driven by a combination of network expansion and high occupancy rates that consistently hover above 72%. The company’s ability to maintain a 20%+ adjusted EBITDA margin amid rising costs indicates strong pricing power and effective cost management, which is a key lever for sustaining profitability as the healthcare environment evolves. Moreover, the strategic capital allocation plan—highlighted by $5–$5.5 billion in 2026 capital spending—focuses on high‑acuity inpatient facilities and outpatient surgical centers, positioning HCA to capture the anticipated shift toward outpatient care and less invasive procedures, a trend that is expected to outpace inpatient volumes.
The digital transformation agenda, particularly the AI‑driven revenue cycle and capacity‑management initiatives, has already yielded measurable improvements in days in accounts receivable and operational efficiency. By standardizing data across its 190 hospitals and 2,500 ambulatory sites, HCA is creating a scalable platform that can be leveraged for future predictive analytics and clinical decision support, potentially driving higher quality outcomes and lower readmission rates. The company’s recent recognition on Healthgrades’ top hospital lists reinforces its clinical excellence narrative, which can enhance payer negotiations and attract higher‑volume referral traffic, thereby supporting incremental revenue growth.
HCA’s shareholder return policy is aggressive yet disciplined: a $10 billion share‑repurchase program, a quarterly dividend increase from $0.72 to $0.78, and $2.6 billion in repurchases during 2025. This signals management confidence in the company’s cash generation capabilities, with operating cash flow projected at $12–$13 billion in 2026, comfortably covering debt service and supporting future capital deployments. The low debt‑to‑adjusted EBITDA leverage range further underpins the firm’s ability to maintain a healthy balance sheet while investing in growth and returning capital to shareholders.
The resiliency program, quantified at a $400 million EBITDA offset in 2026, addresses the projected $600–$900 million headwind from health insurance exchange reforms and the expiration of enhanced premium tax credits. By combining revenue integrity initiatives, cost efficiencies, and capacity management, the program is positioned to partially neutralize policy‑induced revenue erosion, preserving margin expansion. This proactive stance mitigates one of the most significant regulatory risks facing large health systems and can provide a competitive edge over peers less prepared for the exchange transition.
HCA’s outpatient expansion strategy is particularly compelling; the company added approximately 100 new outpatient facilities in 2025 and continues to pursue acquisitions that complement its geographic footprint. Outpatient surgery volumes, though flat in 2024, are projected to grow as patient preference shifts toward minimally invasive procedures and lower cost settings. With 39.7% of total revenues coming from outpatient sources—a figure already above the industry average—HCA is well positioned to capture the long‑term shift toward ambulatory care, reinforcing its revenue diversification and resilience against inpatient downturns.

Bear case

The 2026 guidance explicitly acknowledges a potential $600–$900 million adverse impact on adjusted EBITDA from health insurance exchange reforms, including the expiration of enhanced premium tax credits. This headwind represents a sizable contraction relative to the $4.0 billion in 2025 adjusted EBITDA and could erode operating margins if not fully offset by the resiliency program. The company’s sensitivity to exchange volume declines is further amplified by the projected 15–20% drop in exchange‑derived admissions, which will likely shift a significant portion of that volume into uninsured categories, creating higher uncompensated care costs.
Medicaid supplemental payment programs pose a second critical risk; management projects a $250–$450 million decline in net benefit in 2026 due to state‑level changes in Tennessee, a pause in Texas, and the timing of a retroactive Virginia payment. These programs currently provide a vital subsidy stream that offsets the cost of treating low‑income patients; any reduction directly squeezes margins and increases the burden of cost‑sharing and collections. The unpredictability of state‑level policy shifts adds a layer of regulatory risk that could manifest as sudden cash outflows or loss of revenue streams.
Physician cost pressures are highlighted by CFO Mike Hart, who cautioned that physician costs could rise “in the high single digits” in 2026 versus 2025. Given the industry’s ongoing labor shortage, wage inflation is already in motion, and HCA’s large, multi‑state footprint may amplify negotiation leverage for physicians. Rising provider costs, if not matched by pricing power or efficiency gains, will erode the adjusted EBITDA margin, counteracting the 80‑basis‑point improvement seen in 2025.
The company’s heavy reliance on capital spending—$5–$5.5 billion in 2026—introduces exposure to interest rate fluctuations and debt service costs. While current leverage remains low, a tightening of credit markets could increase borrowing costs or constrain refinancing, squeezing free cash flow. Moreover, capital expenditures in high‑cost acquisition or expansion projects carry execution risk; delays or cost overruns can compress short‑term profitability without delivering the anticipated revenue lift.
Outpatient surgical volume trends show a modest decline; outpatient surgeries dropped 0.5% YoY, and ASCs down 1.5% in Q4 2025. This indicates potential competitive pressure from free‑standing surgical centers or shifting patient preferences toward alternative care models. If HCA cannot reverse this downward trajectory, it risks losing market share in the high‑margin ambulatory segment, which is critical for balancing the lower margins inherent in inpatient services.

The 2026 guidance explicitly acknowledges a potential $600–$900 million adverse impact on adjusted EBITDA from health insurance exchange reforms, including the expiration of enhanced premium tax credits. This headwind represents a sizable contraction relative to the $4.0 billion in 2025 adjusted EBITDA and could erode operating margins if not fully offset by the resiliency program. The company’s sensitivity to exchange volume declines is further amplified by the projected 15–20% drop in exchange‑derived admissions, which will likely shift a significant portion of that volume into uninsured categories, creating higher uncompensated care costs.
Medicaid supplemental payment programs pose a second critical risk; management projects a $250–$450 million decline in net benefit in 2026 due to state‑level changes in Tennessee, a pause in Texas, and the timing of a retroactive Virginia payment. These programs currently provide a vital subsidy stream that offsets the cost of treating low‑income patients; any reduction directly squeezes margins and increases the burden of cost‑sharing and collections. The unpredictability of state‑level policy shifts adds a layer of regulatory risk that could manifest as sudden cash outflows or loss of revenue streams.
Physician cost pressures are highlighted by CFO Mike Hart, who cautioned that physician costs could rise “in the high single digits” in 2026 versus 2025. Given the industry’s ongoing labor shortage, wage inflation is already in motion, and HCA’s large, multi‑state footprint may amplify negotiation leverage for physicians. Rising provider costs, if not matched by pricing power or efficiency gains, will erode the adjusted EBITDA margin, counteracting the 80‑basis‑point improvement seen in 2025.
The company’s heavy reliance on capital spending—$5–$5.5 billion in 2026—introduces exposure to interest rate fluctuations and debt service costs. While current leverage remains low, a tightening of credit markets could increase borrowing costs or constrain refinancing, squeezing free cash flow. Moreover, capital expenditures in high‑cost acquisition or expansion projects carry execution risk; delays or cost overruns can compress short‑term profitability without delivering the anticipated revenue lift.
Outpatient surgical volume trends show a modest decline; outpatient surgeries dropped 0.5% YoY, and ASCs down 1.5% in Q4 2025. This indicates potential competitive pressure from free‑standing surgical centers or shifting patient preferences toward alternative care models. If HCA cannot reverse this downward trajectory, it risks losing market share in the high‑margin ambulatory segment, which is critical for balancing the lower margins inherent in inpatient services.

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	83.85 Bn	12.74	1.10	48.02 Bn
2	THC	Tenet Healthcare Corp	14.98 Bn	8.90	0.70	13.21 Bn
3	DVA	Davita Inc.	13.99 Bn	19.60	1.00	10.63 Bn
4	EHC	Encompass Health Corp	9.72 Bn	16.11	1.60	2.57 Bn
5	ENSG	Ensign Group, Inc	8.90 Bn	24.34	1.69	0.14 Bn
6	UHS	Universal Health Services Inc	8.59 Bn	5.80	0.48	4.71 Bn
7	FMS	Fresenius Medical Care AG	7.67 Bn	-0.08	0.47	8.48 Bn
8	CHE	Chemed Corp	5.97 Bn	23.80	2.35	0.09 Bn

Research Tools

Developers

HCA Healthcare, Inc. (NYSE: HCA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

HCA Healthcare, Inc. (NYSE: HCA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password